Interferon Alpha in the Management of Metastatic Neuroendocrine Tumors: A Retrospective Study in 37 Patients

#738

Introduction: Interferon alpha (IFNα) has not been popular due to perceived lack of efficacy and toxicity profile. Current molecular targeted therapies demonstrate only modest anti-tumor effect with not insignificant toxicity.

Aim(s): To perform a retrospective analysis of IFNα in patients with metastatic NET assessing efficacy and toxicity.

Materials and methods: Thirty-seven patients treated with minimum IFNα 3 million units x 3/week. Mean age 58.6 (24-88) yrs; 26:11 m:f; 21 midgut, seven pancreatic, one hindgut, one bronchial, one thymic and six unknown. Histology: G1 49%; G2 41%; G3 5%: unknown 5%. Seventy-six percent also on somatostatin analogue. Sixty-five percent had progressive disease (PD). CT/MRI imaging; urine 5HIAA and plasma chromagranin A (CgA) and toxicities were recorded.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: MIRVIS E

Authors: Mirvis E, Garcia-Hernandez J, Mandair D, Cheung V, Toumpanakis C,

Keywords: Interferon,